Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review
Open accessThe DOI matches its Crossref record; 121 of the 122 references it cites were found in a registry or an index.
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the latest term for steatotic liver disease associated with metabolic syndrome. MASLD is the most common cause of chronic liver disease and is the leading cause of liver-related morbidity and mortality. It is important that all stakeholders be involved in tackling the public health threat of obesity and obesity-related diseases, including MASLD. A simple and clear assessment and referral pathway using non-invasive tests is essential to ensure that patients with severe MASLD are identified and referred to specialist care, while patients with less severe disease remain in primary care, where they are best managed. While lifestyle intervention is the cornerstone of the management of patients with MASLD, cardiovascular disease risk must be properly assessed and managed because cardiovascular disease is the leading cause of mortality. No pharmacological agent has been approved for the treatment of MASLD, but novel anti-hyperglycemic drugs appear to have benefit. Medications used for the treatment of diabetes and other metabolic conditions may need to be adjusted as liver disease progresses to cirrhosis, especially decompensated cirrhosis. Based on non-invasive tests, the concepts of compensated advanced chronic liver disease and clinically significant portal hypertension provide a practical approach to stratifying patients according to the risk of liver-related complications and can help manage such patients. Finally, prevention and management of sarcopenia should be considered in the management of patients with MASLD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The growing yearly prevalence of Metabolic Dysfunction–non-alcoholic fatty liver disease (MASLD) has emerged as a worldwide public health concern, driven by improved living conditions, evolving lifestyle habits, and the widespread occurrence of obesity, diabetes, and metabolic syndrome.1”
From The Impact of Omega-3 Fatty Acids on Triglyceride Levels in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease: A Meta-Analysis of Randomized Controlled Trials with Subgroup Analysis by Diabetes Status (2026) · cites this paper as [1]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“This is because the clinical definition of MASLD, as previously noted, includes not only the presence of steatosis but also a cardiometabolic context [31,32,33], which cannot be fully reproduced in a monoculture of hepatocyte-like cells.”
From The HepG2 Cell Line as a Model for Studying Metabolic Dysfunction-Associated Steatotic Liver Disease (2026) · cites this paper as [32]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alberti, K. G. M. M., Eckel, R. H., Grundy, S. M., Zimmet, P. Z., Cleeman, J. I., Donato, K. A., Fruchart, J.-C., James, W. P. T., Loria, C. M., & Smith, S. C. (2009) · Circulation · doi:10.1161/circulationaha.109.192644 · Cited by 14,860
Sarcopenia: revised European consensus on definition and diagnosis
Cruz-Jentoft, A. J., Bahat, G., Bauer, J., Boirie, Y., Bruyère, O., Cederholm, T., Cooper, C., Landi, F., Rolland, Y., Sayer, A. A., et al. (2019) · Age and Ageing · doi:10.1093/ageing/afy169 · Cited by 13,818 · cited 2×
“102 Of late, there is a growing interest in studies on the association between sarcopenia and MASLD.”
BackgroundEASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Hypertension · doi:10.1161/hyp.0000000000000065 · Cited by 7,391
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000625 · Cited by 6,185
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
Eslam, M., Newsome, P. N., Sarin, S. K., Anstee, Q. M., Targher, G., Romero-Gomez, M., Zelber-Sagi, S., Wai-Sun Wong, V., Dufour, J.-F., Schattenberg, J. M., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.039 · Cited by 4,472
Self-citationWhelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Hypertension · doi:10.1161/hyp.0000000000000066 · Cited by 4,347
Chalasani, N., Younossi, Z., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K., Charlton, M., & Sanyal, A. J. (2012) · Hepatology · doi:10.1002/hep.25762 · Cited by 3,803
Cited by
Bays, H. E., Kirkpatrick, C. F., Maki, K. C., Toth, P. P., Morgan, R. T., Tondt, J., Christensen, S. M., Dixon, D. L., & Jacobson, T. A. (2024) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2024.04.001 · Cited by 166
Wang, L., Berger, N. A., Kaelber, D. C., & Xu, R. (2024) · Gastroenterology · doi:10.1053/j.gastro.2024.04.029 · Cited by 130
Miller, D. M., McCauley, K. F., & Dunham‐Snary, K. J. (2025) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70132 · Cited by 153
Current and emerging strategies for the prevention of hepatocellular carcinoma
Yeo, Y. H., Abdelmalek, M. F., Khan, S. A., Moylan, C. A., Rodriquez, L. M., Villanueva, A., & Yang, J. D. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-01021-z · Cited by 111
Vesković, M. N., Šutulović, N., Hrnčić, D., Stanojlović, O. P., Μacut, D., & Mladenović, D. R. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45110570 · Cited by 115
Metabolic syndrome: epidemiology, mechanisms, and current therapeutic approaches
Hamooya, B. M., Siame, L., Muchaili, L., Masenga, S. K., & Kirabo, A. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1661603 · Cited by 135
Bays, H. E., Kirkpatrick, C. F., Maki, K. C., Toth, P. P., Morgan, R. T., Tondt, J., Christensen, S. M., Dixon, D. L., & Jacobson, T. A. (2024) · Obesity Pillars · doi:10.1016/j.obpill.2024.100108 · Cited by 126
The Global Burden of Cirrhosis and Other Chronic Liver Diseases in 2021
Tham, E. K. J., Tan, D. J. H., Danpanichkul, P., Ng, C. H., Syn, N. L. X., Koh, B., Lim, R. Y. Z., Wijarnpreecha, K., Teng, M. L. P., Nah, B. K. Y., et al. (2025) · Liver International · doi:10.1111/liv.70001 · Cited by 116
Younossi, Z. M., Razavi, H. A., Sherman, M., Allen, A. M., Anstee, Q. M., Cusi, K. J., Friedman, S. L., Lawitz, E., Lazarus, J. V., Schuppan, D., et al. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70020 · Cited by 78
Simancas-Racines, D., Annunziata, G., Verde, L., Fascì-Spurio, F., Reytor-González, C., Muscogiuri, G., Frias-Toral, E., & Barrea, L. (2025) · Current Obesity Reports · doi:10.1007/s13679-024-00597-6 · Cited by 61
Dysregulated bile acid homeostasis: unveiling its role in metabolic diseases
Wang, Y., Xu, H., Zhou, X., Chen, W., & Zhou, H. (2024) · Medical Review · doi:10.1515/mr-2024-0020 · Cited by 74
Riley, D. R. J., Hydes, T., Hernadez, G., Zhao, S. S., Alam, U., & Cuthbertson, D. J. (2024) · Liver International · doi:10.1111/liv.16016 · Cited by 71
Beygi, M., Ahi, S., Zolghadri, S., & Stanek, A. (2024) · Nutrients · doi:10.3390/nu16142220 · Cited by 75
Song, J., Ma, R., & Yin, L. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1398265 · Cited by 61
The Role of Behavioral Factors on Chronic Diseases—Practice and Knowledge Gaps
Rahelić, V., Perković, T., Romić, L., Perković, P., Majanović, S. K., Pavić, E., & Rahelić, D. (2024) · Healthcare · doi:10.3390/healthcare12242520 · Cited by 87
Understanding the drivers and consequences of early-onset type 2 diabetes
Lim, L.-L., Jones, S., Cikomola, J. C., Hivert, M.-F., & Misra, S. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01012-8 · Cited by 59
Self-citationWinther, J. B., & Holst, J. J. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15693 · Cited by 47
Dong, K., Zheng, Y., Wang, Y., & Guo, Q. (2024) · Scientific Reports · doi:10.1038/s41598-024-80801-8 · Cited by 50
The physiology of MASLD: molecular pathways between liver and adipose tissues
Lee, W., Kipp, Z. A., Bates, E. A., Pauss, S. N., Martinez, G. J., & Hinds, T. D. (2025) · Clinical Science · doi:10.1042/cs20257571 · Cited by 55
López-Pascual, E., Rienda, I., Pérez‐Rojas, J., Rapisarda, A. S., García-Llorens, G., Jover, R., & Castell, J. V. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25105203 · Cited by 49
MASLD: Prevalence, Mechanisms, and Sex-Based Therapies in Postmenopausal Women
Milani, I., Chinucci, M., Leonetti, F., & Capoccia, D. (2025) · Biomedicines · doi:10.3390/biomedicines13040855 · Cited by 38
“These studies suggest improvements in steatohepatitis, reduced progression of fibrosis, and decreased liver-related complications [297,299], supporting these therapies for the treatment of T2D and/or obesity in patients with MASLD [313–316].”
Vaz, J., Jepsen, P., Strömberg, U., Midlöv, P., Eriksson, B., Buchebner, D., & Hagström, H. (2024) · International Journal of Cancer · doi:10.1002/ijc.35097 · Cited by 45
Mu, C., Wang, S., Wang, Z., Tan, J., Yin, H.-Z., Wang, Y., Dai, Z., Ding, D., & Yang, F. (2024) · Annals of Hepatology · doi:10.1016/j.aohep.2024.101774 · Cited by 44
Møller, S., Kimer, N., Hove, J. D., Barløse, M., & Gluud, L. L. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae306 · Cited by 47
Yuan, H., Jung, E.-S., Chae, S., Jung, S., Daily, J. W., & Park, S. (2024) · Nutrients · doi:10.3390/nu16183061 · Cited by 42
Nelson, B. N., & Friedman, J. E. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25115951 · Cited by 41
Lyu, Y., Yang, X., Yang, L., Dai, J., Qin, H., Zhou, Y., Huang, Y., Wang, Y., Wu, D., Shuai, Q., et al. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.07.011 · Cited by 38
Chee, N., Sinnanaidu, R. P., & Chan, W. (2024) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16723 · Cited by 36
Self-citationNelson, L. W., Lee, M. H., Garrett, J. W., Pickhardt, S. G., Warner, J. D., Summers, R. M., & Pickhardt, P. J. (2024) · American Journal of Roentgenology · doi:10.2214/ajr.24.31805 · Cited by 35
Resmetirom: The First Disease‐Specific Treatment for MASH
Mousa, A. M., Mahmoud, M., & AlShuraiaan, G. M. (2025) · International Journal of Endocrinology · doi:10.1155/ije/6430023 · Cited by 46
Puri, M., & Sonawane, S. S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26093988 · Cited by 41
Sex Hormones and Metabolic Dysfunction-Associated Steatotic Liver Disease
Weiskirchen, R., & Lonardo, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26199594 · Cited by 41
Hepatokines and MASLD: The GLP1-Ras-FGF21-Fetuin-A Crosstalk as a Therapeutic Target
Milani, I., Codini, M., Guarisco, G., Chinucci, M., Gaita, C., Leonetti, F., & Capoccia, D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910795 · Cited by 44
Cigarette Smoke Contributes to the Progression of MASLD: From the Molecular Mechanisms to Therapy
Xu, J., Li, Y., Feng, Z., & Chen, H. (2025) · Cells · doi:10.3390/cells14030221 · Cited by 41
Projected Trends in Metabolic Dysfunction–Associated Steatotic Liver Disease Mortality Through 2040
Zhang, X., Linden, S., Levesley, C. R., He, X., Yang, Z., Barnet, S., Cheung, R. C., Ji, F., & Nguyen, M. H. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.16367 · Cited by 40
The global cardiovascular–liver–metabolic syndemic: epidemiology, trends and challenges
Chew, N., Mehta, A., Goh, R. J. L., Koh, J., Chen, Y., Chong, B., Chan, M. Y., Khan, M. S., Muthiah, M. D., Butler, J., et al. (2025) · Nature Reviews Cardiology · doi:10.1038/s41569-025-01220-4 · Cited by 45
Reshef, N., Gophna, U., Reshef, L., Konikoff, F. M., Gabay, G., Zornitzki, T., Knobler, H., & Maor, Y. (2024) · Nutrients · doi:10.3390/nu16111571 · Cited by 37
Implications of innate immune sexual dimorphism for MASLD pathogenesis and treatment
Booijink, R. S., Ramachandran, P., & Bansal, R. (2024) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2024.05.004 · Cited by 34
Jin, Y., Wang, X., Chen, K., Chen, Y., Zhou, L., Zeng, Y., Zhou, Y., Pan, Z., Wang, D., Li, Z., et al. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02220-y · Cited by 45
Environmental Pollutants, Occupational Exposures, and Liver Disease
Beier, J. I., Luo, J., Vanderpuye, C.-M., Brizendine/Ames, P. M., Muddasani, P., Bolatimi, O. E., Heinig, S. A., Ekuban, F. A., Siddiqui, H., Ekuban, A., et al. (2025) · Seminars in Liver Disease · doi:10.1055/a-2540-2861 · Cited by 41
The Relationship between Pathogenesis and Possible Treatments for the MASLD-Cirrhosis Spectrum
Vidal‐Cevallos, P., Sorroza-Martínez, A. P., Chávez-Tapia, N. C., Uribe, M., Montalvo-Jave, E. E., & Nuño‐Lámbarri, N. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084397 · Cited by 37
Jurek, J. M., Zabłocka-Słowińska, K. A., Clavero-Mestres, H., Gutiérrez, L. R., Camaron, J., & Auguet, T. (2025) · Nutrients · doi:10.3390/nu17071257 · Cited by 43
Association of temporal MASLD with type 2 diabetes, cardiovascular disease and mortality
Han, E., Han, K., Lee, Y., Kim, K., Hong, S., Park, J. H., & Park, C. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02824-3 · Cited by 42
Galasso, L., Cerrito, L., Maccauro, V., Termite, F., Mignini, I., Esposto, G., Borriello, R., Ainora, M. E., Gasbarrini, A., & Zocco, M. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137191 · Cited by 34
Qi, R., Lu, L., He, T., Zhang, L., Lin, Y., & Bao, L. (2024) · European Radiology · doi:10.1007/s00330-024-11119-2 · Cited by 35
Berdowska, I., Matusiewicz, M., & Fecka, I. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26062394 · Cited by 35
Mohiuddin, M. S., Neha, N. T., Mahir, J. U. K., Shakib, F. A. F., Alam, M. A., Wahiduzzaman, M., Barua, R., Shimu, S. J., Rahman, M. M., Hossain, M. R., et al. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1669478 · Cited by 43
Wade, H., Pan, K., Zhang, B., Zheng, W., & Su, Q. (2024) · eGastroenterology · doi:10.1136/egastro-2024-100115 · Cited by 32
Wang, Y., Fleishman, J. S., Li, T., Li, Y., Ren, Z., Chen, J., & Ding, M. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1336216 · Cited by 31
Guo, M., Liu, R., Zhang, F., Qu, J., Yang, Y., & Li, X. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107409 · Cited by 35
Bile acids and their receptors in hepatic immunity
Fiorucci, S., Marchianò, S., Distrutti, E., & Biagioli, M. (2025) · Liver Research · doi:10.1016/j.livres.2025.01.005 · Cited by 31
Insulin resistance and cancer: molecular links and clinical perspectives
Caturano, A., Erul, E., Nilo, R., Nilo, D., Russo, V., Rinaldi, L., Acierno, C., Gemelli, M. T., Ricotta, R., Sasso, F. C., et al. (2025) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-025-05245-8 · Cited by 30
Non-Invasive Tests as a Replacement for Liver Biopsy in the Assessment of MASLD
Frączek, J., Sowa, A., Agopsowicz, P., Migacz, M., Dylińska-Kala, K., & Holecki, M. T. (2025) · Medicina · doi:10.3390/medicina61040736 · Cited by 41
Diagnostic performance of sixteen biomarkers for MASLD: A study in a Mexican cohort
Priego-Parra, B. A., Reyes-Diaz, S. A., Alvarez, H. R. O., Bernal-Reyes, R., Icaza-Chávez, M. E., Vázquez, S., Amieva‐Balmori, M., Vivanco-Cid, H., Velasco, J. A. V.-R., Gracia‐Sancho, J., et al. (2024) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2024.102400 · Cited by 28
Bucarey, J. L., Paules, E. M., Trujillo‐Gonzalez, I., & Espinosa, A. (2024) · Antioxidants · doi:10.3390/antiox13111363 · Cited by 35
Pasta, A., Formisano, E., Calabrese, F., Marabotto, E., Furnari, M., Bodini, G., Torres, M. C. P., Pisciotta, L., Giannini, E. G., & Zentilin, P. (2025) · Microorganisms · doi:10.3390/microorganisms13020241 · Cited by 24
Lv, X., Nie, C., Shi, Y., Qiao, Q., Gao, J. X., Zou, Y., Yang, J., Chen, L., & Hou, X. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02382-9 · Cited by 28
Statin use and liver-related prognosis among patients with MASLD
Yun, B., Park, H., Lee, J., Kim, B. K., & Yoon, J. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101313 · Cited by 35
Environmental exposures and the risk of hepatocellular carcinoma
Rayapati, D., McGlynn, K. A., Groopman, J. D., & Kim, A. K. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000627 · Cited by 28
Gallo, G., Nalli, G., Baratta, F., Desideri, G., & Savoia, C. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26168081 · Cited by 27
Jarmakiewicz-Czaja, S., Sokal-Dembowska, A., & Filip, R. (2025) · Medicina · doi:10.3390/medicina61020192 · Cited by 32
Romeo, M., Dallio, M., Napolitano, C., Basile, C., Nardo, F. D., Vaia, P., Iodice, P., & Federico, A. (2025) · Diagnostics · doi:10.3390/diagnostics15030252 · Cited by 31
Targeting MASLD and MASH in the US Hispanic/Latino Population: A Review
Cumpian, N. A., Gutierrez, J. A., Wu, W., & Saab, S. (2025) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2025.4769 · Cited by 22
Allen, A. M., Charlton, M., Cusi, K. J., Harrison, S. A., Kowdley, K. V., Noureddin, M., & Shubrook, J. H. (2024) · Postgraduate Medicine · doi:10.1080/00325481.2024.2325332 · Cited by 29
Role of MASLD in CVD: A review of emerging treatment options
Mollace, R., Longo, S., Nardin, M., Tavernese, A., Musolino, V., Cardamone, A., & Federici, M. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111891 · Cited by 29
Khanmohammadi, S., & Kuchay, M. S. (2024) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes24004 · Cited by 27
Molecular Regulation and Therapeutic Targeting of VLDL Production in Cardiometabolic Disease
Burks, K. H., Stitziel, N. O., & Davidson, N. O. (2024) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2024.101409 · Cited by 27
Galicia‐Moreno, M., Monroy-Ramírez, H. C., Caloca-Camarena, F., Arceo-Orozco, S., Muriel, P., Sandoval-Rodriguez, A. S., Garcia-Bañuelos, J. J., García, A., Navarro‐Partida, J., & Armendáriz‐Borunda, J. (2024) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-024-03539-0 · Cited by 25
Inhibiting Ferroptosis Prevents the Progression of Steatotic Liver Disease in Obese Mice
Park, G.-C., Bang, S.-Y., Kim, J. M., Shin, S., Cheon, Y.-I., Kim, K. M., Park, H., Sung, E., Lee, M., Lee, J., et al. (2024) · Antioxidants · doi:10.3390/antiox13111336 · Cited by 29
Flores-Peña, R., Monroy-Ramírez, H. C., Caloca-Camarena, F., Arceo-Orozco, S., Salto-Sevilla, J. A., Galicia‐Moreno, M., & Armendáriz‐Borunda, J. (2025) · Antioxidants · doi:10.3390/antiox14080979 · Cited by 27
The complement system in lipid-mediated pathologies
Alić, L., Dendinovic, K., & Papac-Miličević, N. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1511886 · Cited by 20
Jang, H., Joung, H., Chu, J., Cho, M., Kim, Y.-W., Kim, K. H., Shin, C. H., Lee, J., & Ha, J. (2024) · Nutrients · doi:10.3390/nu16244260 · Cited by 21
Han, J., Jeong, H., Lee, C., Sung, A., Choi, Y. H., & Jung, Y. (2025) · Liver International · doi:10.1111/liv.70224 · Cited by 24
Metabolic-associated fatty liver disease and sarcopenia: A double whammy
Viswanath, A., Fouda, S., Fernandez, C. J., & Pappachan, J. M. (2024) · World Journal of Hepatology · doi:10.4254/wjh.v16.i2.152 · Cited by 22
Venn-Watson, S. K. (2024) · Metabolites · doi:10.3390/metabo14070355 · Cited by 22
Armstrong, M. J., Okanoue, T., Palle, M. S., Sejling, A., Tawfik, M., & Roden, M. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16065 · Cited by 21
The Expanding Scope of GLP-1 Receptor Agonists: Six Uses Beyond Diabetes
Sheth, K., Kim, S., Porterfield, L. R., Virani, S. S., Wadhwani, S., & Vaughan, E. M. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01319-6 · Cited by 21
Chen, Y., Xie, C., Lei, Y., Ye, D., Wang, L., Xiong, F., Wu, H., He, Q., Zhou, H., Li, L., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116582 · Cited by 25
MASLD vs. NAFLD: A better definition for children with obesity at higher risk of kidney damage
Sessa, A. D., Guarino, S., Umano, G. R., del Giudice, E. M., & Marzuillo, P. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.10.021 · Cited by 19
Baek, S., & Yoon, J. (2024) · Biomolecules · doi:10.3390/biom14111468 · Cited by 22
Bagnato, C. B., Bianco, A., Bonfiglio, C., Franco, I., Verrelli, N., Carella, N., Shahini, E., Zappimbulso, M., Giannuzzi, V., Pesole, P. L., et al. (2024) · Nutrients · doi:10.3390/nu16234225 · Cited by 27
Time Restricted Eating: A Valuable Alternative to Calorie Restriction for Addressing Obesity?
Parrotta, M. E., Colangeli, L., Scipione, V., Vitale, C., Sbraccia, P., & Guglielmi, V. (2025) · Current Obesity Reports · doi:10.1007/s13679-025-00609-z · Cited by 21
Karahan, T. Ö., Kenger, E. B., & Yilmaz, Y. N. (2025) · Journal of Human Nutrition and Dietetics · doi:10.1111/jhn.70033 · Cited by 20
Increased Mortality Among Lean Versus Non‐Lean Adults With MASLD: A Multicenter Study
Ghani, L. K., Aboona, M. B., Faulkner, C., Rangan, P., Rubin, M. I. N., Han, M. A. T., Fallon, M. B., Chen, V. L., & Wijarnpreecha, K. (2025) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.17015 · Cited by 22
Targeting ferroptosis as a therapeutic strategy for hepatotoxicity
Hemmati, N., Anoush, M., Kiasari, B. A., & Torkamani, A. (2025) · Toxicology Reports · doi:10.1016/j.toxrep.2025.102137 · Cited by 25
New Biomarkers in Liver Fibrosis: A Pass through the Quicksand?
Tagliaferro, M., Marino, M., Basile, V., Pocino, K., Rapaccini, G. L., Ciasca, G., Basile, U., & Carnazzo, V. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14080798 · Cited by 23
Lee, J. H., Kim, S., Lee, Y., Kwon, Y., & Lee, J. (2024) · Nutrients · doi:10.3390/nu16203551 · Cited by 23
Vesković, M. N., Pejović, M., Šutulović, N., Hrnčić, D., Rašić-Marković, A., Stanojlović, O. P., & Mladenović, D. R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137405 · Cited by 20
Advancing hepatotoxicity assessment: current advances and future directions
Kim, Y., Kim, Y., & Kim, Y. (2025) · Toxicological Research · doi:10.1007/s43188-025-00289-w · Cited by 22
Zhou, J., & Han, J. H. (2024) · BMC Public Health · doi:10.1186/s12889-024-20161-0 · Cited by 18
Barbhuiya, P. A., Ahmed, A., Dutta, P. P., Sen, S., & Pathak, M. P. (2025) · Current Nutrition Reports · doi:10.1007/s13668-024-00598-w · Cited by 19
Lorek, D., Łupina, K., Bisaga, W., Malicki, D., Stępień, W., Kumor, L., & Janczura, J. (2025) · Korean Journal of Family Medicine · doi:10.4082/kjfm.25.0027 · Cited by 28
Huber, Y., Hofmann, L. J., Prochaska, J. H., Koeck, T., Chalabi, J., Pfeiffer, N., Beutel, M. E., Strauch, K., Lackner, K. J., Tuescher, O., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.70053 · Cited by 19
Elsabaawy, M. (2024) · Clinical and Experimental Medicine · doi:10.1007/s10238-024-01493-y · Cited by 21
Abdallah, H., Khalil, M., Awada, E., Lanza, E., Ciaula, A. D., & Portincasa, P. (2025) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2025.05.018 · Cited by 18
Integrated Patient Digital and Biomimetic Twins for Precision Medicine: A Perspective
Miedel, M. T., Schurdak, M. E., Stern, A. M., Soto–Gutiérrez, A., Strobl, E. V., Behari, J., & Taylor, D. L. (2025) · Seminars in Liver Disease · doi:10.1055/a-2649-1560 · Cited by 21
Wang, H., Liu, X., Wang, C., Yu, S., Yang, X., Cao, X., Luo, M., Liu, S., & Zhang, C. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1611400 · Cited by 23
Hepatic Zonation in MASLD: Old Question, New Challenge in the Era of Spatial Omics
Paolini, E., Longo, M., Meroni, M., & Dongiovanni, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262110701 · Cited by 21
Klaus, J. B., Goerke, U., Klarhöfer, M., Keerthivasan, M., Jung, B. A., Berzigotti, A., Ebner, L., Roos, J. E., Christe, A., Obmann, V. C., et al. (2024) · Investigative Radiology · doi:10.1097/rli.0000000000001084 · Cited by 23
The Link between Metabolic Syndrome and the Brain
Zouridis, S., Nasir, A. B., Aspichueta, P., & Syn, W. (2024) · Digestion · doi:10.1159/000541696 · Cited by 21
Metadata
- Authors
- Chan, W.-K., Chuah, K.-H., Rajaram, R. B., Lim, L.-L., Ratnasingam, J., & Vethakkan, S. R.
- Affiliations
- University of Malaya (MY)
- Chinese University of Hong Kong (HK)
- Corresponding author
- Chan, Wah-Kheong
- Venue
- Journal of Obesity & Metabolic Syndrome
- Published
- 2023-09-13
- Volume
- 32
- Issue
- 3
- Pages
- 197-213
- ISSN
- 2508-6235 (ISSN-L)
- 2508-7576
- PMC
- PMC10583766
- OpenAlex
- W4386704735
- Cited by
- 776
- References
- 122
- Citations by year
- 2026: 245 · 2025: 342 · 2024: 183 · 2023: 5
- FWCI
- 30.29
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0/ (tdm)
- Locations
- Journal of Obesity & Metabolic Syndrome (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Keywords
- non-alcoholic fatty liver disease, metabolic syndrome, obesity, chronic liver disease, non-invasive liver assessment, referral pathways, lifestyle intervention, cardiovascular risk, anti-hyperglycemic drugs, liver cirrhosis, decompensated cirrhosis, compensated advanced chronic liver disease, clinically significant portal hypertension, sarcopenia, liver complications
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.